Spectrum Pharmaceuticals (SPPI) 10-Q2013 Q3 Quarterly report

Content analysis

Filed: 18 Nov 13, 12:00am

Date: November 18, 2013

/s/ Rajesh C. Shrotriya

Rajesh C. Shrotriya, MD

Chairman, Chief Executive Officer and President

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abated, absent, banker, CEO, CFO, commonly, confidence, corrected, correction, counteract, CVR, deficiency, deficit, discovered, essential, exhausted, FIFO, flat, greatest, hiring, incidental, ineffective, inItem, inPart, ix, licensee, located, Mark, methotrexate, misstatement, nature, nondeductible, Notwithstanding, outsourcing, overstatement, payout, perspective, Philadelphia, proper, quantitative, regularly, remote, responding, restructure, SeeItem, Sherwin, slight, SPC, tabular, training, vi, vii, viii, xi

Removed: accumulate, achieve, Acting, actively, added, advancing, affirmative, agency, aging, aid, al, alleged, analogue, analyzing, annum, anticipate, applied, auction, authorize, authorized, back, backed, banking, bankruptcy, began, benchmark, biotech, borrow, brand, broad, build, burn, cancelable, care, carried, challenging, characterization, charge, chargeback, collaborate, collaborative, collaborator, commencing, commensurate, commitment, community, comparative, complement, comprising, compromised, confirming, consecutive, consolidate, constantly, continually, contracted, controlling, conversion, converted, counterparty, covered, create, crediting, crunch, damaged, dating, death, decision, dedicated, delivered, delivery, department, deploy, derecognition, designing, desired, destroyed, detail, devote, DHFR, dihydrofolate, dilution, discipline, dislocation, distribute, District, DNA, dramatic, drew, efficient, eighteen, eighty, endpoint, enhanced, enzyme, estimation, evaluating, evolved, expand, expansion, expeditiously, expensing, explore, extension, extensive, extremely, faced, facilitate, fact, FASB, file, Finally, financed, fiscally, floor, folate, footnote, foregoing, forfeiture, formed, forward, funding, generation, goal, governed, grant, growing, half, HDAC, hematological, hospital, hundred, ibritumomab, incentive, incorrectly, inhibition, inhibitor, initiate, initiated, instillation, integration, intend, intercompany, interfering, issuable, large, launched, lean, leveraging, levoleucovorin, liaison, managed, materialize, MDs, mechanism, Medicaid, metabolic, misleading, monetize, monitored, motivated, NDA, necessity, negatively, noncompliance, offered, offering, opened, operation, operational, ordered, organization, organized, outlook, palliative, participant, past, pathway, payroll, permitted, persuasive, plaintiff, preauthorization, preferentially, prescription, principally, promote, promotional, prudent, pursue, pursuit, purview, qualify, quality, Quebec, reaching, recent, recipient, reducing, reductase, reevaluate, regular, relationship, repaid, reserve, resold, response, restocking, retention, return, returned, reversed, RNA, roll, RTU, Rule, running, safely, salary, science, secure, separately, served, sharing, shipped, shown, similarity, solid, source, specialty, spot, streamlining, subjective, substance, substitutable, suggest, suitably, supervision, support, supported, talent, therapeutic, thirty, tiuxetan, tumor, typically, uncured, understanding, undiscounted, unique, unrecognized, unvested, updated, usage, USD, user, validate, variety, varying, vest, vested, violation, volatile, voluntarily, WAC, warrant, worth

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SPPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Rajesh C. Shrotriya, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Quarterly Report of Spectrum Pharmaceuticals, Inc. on Form 10-Q for the quarterly period ended September 30, 2013 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents in all material respects the financial condition and results of operations of Spectrum Pharmaceuticals, Inc.

This certification accompanies the Report pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities and Exchange Act of 1934, or otherwise subject to the liability of that section. This certification shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, or, the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporated by reference.